Akineton
(Biperiden)ApprovedSmall molecule
AbbVieAkineton is one of 86 small molecule programs targeting Cocaine Dependence. It is currently in Approved.
2
Indications
5
Total Trials
1
Active Trials
85
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPhase 3
Depacon
AbbViePhase 3
Zonegran
AAzurity Pharmaceuticals
Phase 3
Actemra
RochePhase 3
Akineton
AbbVieApproved
GWP42003-P
Jazz PharmaceuticalsPhase 3
Immunoglobulin
SanofiPhase 3
Lamictal
GSKPhase 3
Carisbamate
SSK Life Science, Inc.
Phase 3
Usual Treatment
UUniversity Hospital, Grenoble
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Cocaine Dependence1 trial
Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence
Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00495183·108 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
AKINETON
NDA NDA012418
Jan 1, 1982
AKINETON
NDA NDA012003
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biperiden. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]